INO-4500 / Inovio - LARVOL DELTA

Safety, tolerability, and immunogenicity of INO-4500, a synthetic DNA-based vaccine against Lassa virus, in a phase 1b clinical trial in healthy Ghanaian adults. (PubMed, Front Immunol) - P1 | "These findings support further clinical development of INO-4500 as a potential preventive vaccine to reduce LF-associated morbidity and mortality in endemic regions. https://clinicaltrials.gov, identifier NCT04093076."

Clinical • Journal • P1 data • Hematological Disorders • Infectious Disease • Otorhinolaryngology

Lassa fever: A comprehensive review of virology, clinical management, and global health implications. (PubMed, World J Virol) - "While ribavirin remains the main antiviral treatment, its effectiveness depends heavily on early administration. Currently, no approved vaccine exists; however, promising candidates like vesicular stomatitis virus (VSV)ΔG-LASVGPC, INO-4500, and measles virus-based (MV)-LASV are undergoing preclinical and early-phase clinical evaluation, exhibiting encouraging immune responses in animal and human studies. A comprehensive strategy combining public health education, rodent control measures, robust infection prevention in clinical settings, and international cooperation in vaccine and drug research is essential to curb the impact of LF."

Journal • Review • Cerebral Hemorrhage • Hematological Disorders • Infectious Disease • Inflammation • Malaria • Measles

The DNA-based Lassa vaccine INO-4500 confers durable protective efficacy in cynomolgus macaques against lethal Lassa fever. (PubMed, Commun Med (Lond)) - "These studies demonstrate that INO-4500 can provide short- and long-term protection in NHPs from lethal LASV challenge."

Journal • Infectious Disease • IFNG

Lassa fever vaccine candidates: A scoping review of vaccine clinical trials. (PubMed, Trop Med Int Health) - "Though LF vaccine development is still in early stages, current progress towards a safe and effective vaccine is encouraging."

Journal • Review • Infectious Disease

Dose-ranging Study: Safety, Tolerability and Immunogenicity of INO-4500 in Healthy Volunteers in Ghana (clinicaltrials.gov) - P1 | N=220 | Completed | Sponsor: Inovio Pharmaceuticals | Active, not recruiting ➔ Completed

Combination therapy • Trial completion • Infectious Disease • IFNG

Dose-ranging Study: Safety, Tolerability and Immunogenicity of INO-4500 in Healthy Volunteers in Ghana (clinicaltrials.gov) - P1; N=220; Active, not recruiting; Sponsor: Inovio Pharmaceuticals; Recruiting ➔ Active, not recruiting

Clinical • Combination therapy • Enrollment closed • Infectious Disease • IFNG

Dose-ranging Study: Safety, Tolerability and Immunogenicity of INO-4500 in Healthy Volunteers in Ghana (clinicaltrials.gov) - P1; N=220; Recruiting; Sponsor: Inovio Pharmaceuticals; Not yet recruiting ➔ Recruiting

Clinical • Combination therapy • Enrollment open • Infectious Disease • IFNG

Safety, Tolerability and Immunogenicity of INO-4500 in Healthy Volunteers (clinicaltrials.gov) - P1; N=60; Completed; Sponsor: Inovio Pharmaceuticals; Active, not recruiting ➔ Completed

Clinical • Trial completion • Infectious Disease • IFNG

Dose-ranging Study: Safety, Tolerability and Immunogenicity of INO-4500 in Healthy Volunteers in Ghana (clinicaltrials.gov) - P1; N=220; Not yet recruiting; Sponsor: Inovio Pharmaceuticals; Trial completion date: Mar 2022 ➔ Jun 2022; Trial primary completion date: Mar 2022 ➔ Jun 2022

Clinical • Combination therapy • Trial completion date • Trial primary completion date • Infectious Disease • IFNG

Dose-ranging Study: Safety, Tolerability and Immunogenicity of INO-4500 in Healthy Volunteers in Ghana (clinicaltrials.gov) - P1; N=220; Not yet recruiting; Sponsor: Inovio Pharmaceuticals; Trial completion date: Dec 2021 ➔ Mar 2022; Trial primary completion date: Dec 2021 ➔ Mar 2022

Clinical • Combination therapy • Trial completion date • Trial primary completion date • IFNG

Dose-ranging Study: Safety, Tolerability and Immunogenicity of INO-4500 in Healthy Volunteers in Ghana (clinicaltrials.gov) - P1; N=220; Not yet recruiting; Sponsor: Inovio Pharmaceuticals; Initiation date: Mar 2020 ➔ Jun 2020

Clinical • Combination therapy • Trial initiation date • Immunology • IFNG